Ticker LaunchReverse merger · Completed · OCGN
Ocugen, Inc.
Reverse merger with Histogenics Corporation (HSGX)
Ocugen, Inc. merged into Histogenics Corporation (HSGX), a Nasdaq-listed restorative cell therapy developer that sold its NeoCart program, in a reverse merger that takes the private company public. The deal was announced on Apr 5, 2019 and closed on Sep 27, 2019. The combined company trades as Ocugen, Inc. (OCGN) on Nasdaq.
Ocugen, Inc. is a clinical-stage biopharmaceutical company developing therapies for rare and underserved eye diseases, including the OCU400 gene therapy candidate for inherited retinal degenerations.
- Status
- Completed
- Private company
- Ocugen, Inc.
- Public company
- Histogenics Corporation (HSGX)
- Public company business before
- Nasdaq-listed restorative cell therapy developer that sold its NeoCart program
- Announced
- Apr 5, 2019
- Closed
- Sep 27, 2019
- Combined company
- Ocugen, Inc. (OCGN)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Oct 1, 2019
- Closing press release / exhibit
- All filings on EDGAR CIK 1372299
Other completed reverse mergers
- Shengshi International Holdings Co., Ltd.into Galem Group Inc. (renamed Shengshi Elevator International Holding Group Inc.) · Oct 1, 2019
- American Aviation Technologies LLCinto Banjo & Matilda, Inc. · Sep 30, 2019
- Conperin Group Inc.into Union Bridge Holdings Limited · Sep 24, 2019
- Ngen Technologies USA Corpinto Liberated Solutions, Inc. · Sep 16, 2019
- AM (Advanced Micro) Biosciences, Inc.into Cosmo Ventures, Inc. · Sep 10, 2019
- Rucheng Wenchuan Gas Co., Ltd.into Jialijia Group Corporation Limited · Aug 30, 2019